Callisto Pharmaceuticals Inc - Prospectus filed pursuant to Rule 424(b)(3) (424B3)
30 Enero 2008 - 12:55PM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(3)
File Number 333-145989
PROSPECTUS
SUPPLEMENT NO. 1, DATED JANUARY 30, 2008
(To
Prospectus dated September 26, 2007)
(Registration
No. 333-145989)
CALLISTO
PHARMACEUTICALS, INC.
This Prospectus Supplement No. 1
supplements our Prospectus dated September 26, 2007. The shares that are the subject of the
Prospectus have been registered to permit their resale to the public by the
selling stockholders named in the Prospectus.
We are not selling any shares of common stock in this offering and
therefore will not receive any proceeds from this offering. You should read this Prospectus Supplement No. 1
together with the Prospectus.
The table set forth in the section of the Prospectus entitled Selling Stockholders is hereby updated to reflect the transfer of Series B Convertible Preferred Stock and warrants and the underlying common stock from Credit des Alpes Ltd. to Eureka Sciences Incubator S.A.R.L. The selling stockholder may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time or from time to time since the dates on which it provided the information regarding the shares beneficially owned by it, all or a portion of the shares beneficially owned by it in transactions registered under other effective registration statements or exempt from the registration requirements of the Securities Act.
|
|
|
After the Offering
|
|
Selling
Stockholder
|
|
Number of Shares Beneficially Owned Prior to the Offering
|
|
Number of
Shares Offered
|
|
Number of
Shares
|
|
Percent of Shares Beneficially Owned (1)
|
|
Credit des Alpes Ltd.
|
|
0
|
|
0
|
|
|
|
|
|
Eureka Sciences Incubator
S.A. R.L.
|
|
1,138,467
|
|
400,000
|
|
738,467
|
|
1.6
|
|
(1) Based on 47,143,161 shares of common stock issued and
outstanding as of January 30, 2008.
Our common stock is listed on
the American Stock Exchange under the symbol KAL.
Neither
the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or passed upon the accuracy or
adequacy of this Prospectus Supplement.
Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement is January 30,
2008.
Callisto (AMEX:KAL)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Callisto (AMEX:KAL)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
Real-Time news about Callisto Pharmaceuticals, (American Stock Exchange): 0 recent articles
Más de Callisto Pharmaceuticals Inc Artículos de Noticias